Royal Bank Of Canada Issues Pessimistic Forecast for Pharvaris (NASDAQ:PHVS) Stock Price

Pharvaris (NASDAQ:PHVS) had its price target cut by research analysts at Royal Bank Of Canada from $52.00 to $51.00 in a research report issued on Monday,Benzinga reports. The brokerage currently has an “outperform” rating on the stock. Royal Bank Of Canada’s price target points to a potential upside of 83.19% from the stock’s current price.

PHVS has been the topic of a number of other reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Pharvaris in a research note on Thursday, January 22nd. HC Wainwright restated a “buy” rating and set a $60.00 price target on shares of Pharvaris in a research note on Tuesday, March 3rd. Finally, Wall Street Zen cut shares of Pharvaris from a “hold” rating to a “sell” rating in a research note on Sunday. Ten research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Pharvaris currently has a consensus rating of “Moderate Buy” and a consensus price target of $42.80.

Pharvaris Stock Down 1.9%

PHVS opened at $27.84 on Monday. The stock has a market cap of $1.51 billion, a price-to-earnings ratio of -8.26 and a beta of -2.58. Pharvaris has a twelve month low of $11.51 and a twelve month high of $29.85. The company’s 50-day moving average price is $27.08 and its two-hundred day moving average price is $25.48.

Institutional Trading of Pharvaris

A number of institutional investors have recently modified their holdings of the business. General Atlantic L.P. lifted its stake in shares of Pharvaris by 6.6% during the 3rd quarter. General Atlantic L.P. now owns 8,031,252 shares of the company’s stock valued at $200,380,000 after buying an additional 500,000 shares in the last quarter. Foresite Capital Management IV LLC lifted its stake in shares of Pharvaris by 8.3% during the 3rd quarter. Foresite Capital Management IV LLC now owns 4,778,581 shares of the company’s stock valued at $119,226,000 after buying an additional 368,000 shares in the last quarter. venBio Partners LLC lifted its stake in shares of Pharvaris by 8.2% during the 3rd quarter. venBio Partners LLC now owns 4,639,304 shares of the company’s stock valued at $115,751,000 after buying an additional 350,000 shares in the last quarter. Deerfield Management Company L.P. lifted its stake in Pharvaris by 21.1% in the 3rd quarter. Deerfield Management Company L.P. now owns 2,442,464 shares of the company’s stock worth $60,939,000 after purchasing an additional 425,000 shares in the last quarter. Finally, Commodore Capital LP lifted its stake in Pharvaris by 26.5% in the 3rd quarter. Commodore Capital LP now owns 2,418,476 shares of the company’s stock worth $60,341,000 after purchasing an additional 507,043 shares in the last quarter.

Pharvaris News Summary

Here are the key news stories impacting Pharvaris this week:

• Positive Sentiment: Wedbush raised its price target to $42 and kept an “outperform” rating, implying roughly a 50% upside from current levels — a near-term bullish catalyst from an influential equity shop. Benzinga
• Positive Sentiment: HC Wainwright issued long-range FY2030 estimates calling for EPS of $5.37 and maintains a “Buy” rating with a $60 target — a highly constructive, bullish long-term projection that signals analysts expect strong eventual profitability. MarketBeat
• Neutral Sentiment: Brokerage consensus remains favorable overall — PHVS is reported to have an average rating of “Moderate Buy,” reflecting broad analyst support but varied views on timing and magnitude of upside. American Banking News
• Neutral Sentiment: Royal Bank of Canada trimmed its price target slightly from $52 to $51 but left an “outperform” rating in place — a small downgrade in projection that still implies large upside, so its market impact is muted. Benzinga
• Negative Sentiment: Coverage and commentary are questioning whether Phase 3 completion and projected 2025 losses change Pharvaris’ investment narrative; concerns about near-term profitability and how the market will value post‑Phase 3 commercialization are weighing on sentiment. Yahoo Finance

Pharvaris Company Profile

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.